Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 7/20 | 0.48 |
| ▸ | CCR1 | P32246 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | PMM2 | O15305 | 1/20 | 0.44 |
| ▸ | MPI | P34949 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | PHOSPHO1 | Q8TCT1 | 1/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.43 |
| ▸ | ESRRA | P11474 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9609077 | 0.91 | NR3C1 (0.46) | NR3C1CCR1MEN1KMT2ARXFP1 | |
| SCHEMBL303757 | 0.88 | CCR1 (0.55) | CCR1MEN1KMT2ARXFP1TP53 | |
| SCHEMBL13884763 | 0.88 | NR3C1 (0.44) | NR3C1CCR1MEN1KMT2ARXFP1 | |
| SCHEMBL1776385 | 0.87 | MAPT (0.46) | NR3C1MEN1KMT2ATP53GAA | |
| SCHEMBL303719 | 0.84 | TDP1 (0.45) | NR3C1CCR1KMT2ARAB9AALDH1A1 | |
| SCHEMBL4401018 | 0.81 | NPC1 (0.56) | NR3C1KMT2ARXFP1TP53RAB9A | |
| SCHEMBL9609001 | 0.80 | NR3C1 (0.44) | NR3C1CCR1MEN1KMT2ARXFP1 | |
| SCHEMBL304081 | 0.78 | RAB9A (0.47) | NR3C1MEN1KMT2ARAB9AALDH1A1 | |
| SCHEMBL304020 | 0.78 | HTT (0.54) | CCR1RXFP1ESRRAALDH1A1MAPT | |
| SCHEMBL5007660 | 0.77 | MEN1 (0.48) | CCR1MEN1KMT2ARXFP1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2013185-B1 | NOVEL COMPOUNDS | GLAXO GROUP LTD (GB) | 2012-05-30 | — | — | EP | disclosed |
| EP-2013185-B1 | NOVEL COMPOUNDS | GLAXO GROUP LTD (GB) | 2012-05-30 | — | — | EP | disclosed |
| US-8178573-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2012-05-15 | — | — | US | disclosed |
| US-8178573-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2012-05-15 | — | — | US | disclosed |
| US-8178573-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2012-05-15 | — | — | US | disclosed |
| US-7943651-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2011-05-17 | — | — | US | disclosed |
| US-7943651-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2011-05-17 | — | — | US | disclosed |
| US-7943651-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2011-05-17 | — | — | US | disclosed |
| WO-2009074590-A1 | N- (2 { [1-PHENYL-1H-INDAZ0L-4-YL] AMINO} PROPYL) -SULFONAMIDE DERIVATIVES AS NON-STEROIDAL GLUCOCORTICOID RECEPTOR LIGANDS FOR THE TREATMENT OF INFLAMMATIONS | GLAXO GROUP LIMITED (GB) | 2009-06-18 | — | — | WO | disclosed |
| WO-2009074590-A1 | N- (2 { [1-PHENYL-1H-INDAZ0L-4-YL] AMINO} PROPYL) -SULFONAMIDE DERIVATIVES AS NON-STEROIDAL GLUCOCORTICOID RECEPTOR LIGANDS FOR THE TREATMENT OF INFLAMMATIONS | GLAXO GROUP LIMITED (GB) | 2009-06-18 | — | — | WO | disclosed |
| US-20090111866-A1 | Novel Compounds | GLAXO WELLCOME HOUSE (GB) | 2009-04-30 | — | — | US | disclosed |
| US-20090111866-A1 | Novel Compounds | GLAXO WELLCOME HOUSE (GB) | 2009-04-30 | — | — | US | disclosed |
| US-20090111866-A1 | Novel Compounds | GLAXO WELLCOME HOUSE (GB) | 2009-04-30 | — | — | US | disclosed |
| US-20070265326-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-11-15 | — | — | US | disclosed |
| US-20070265326-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-11-15 | — | — | US | disclosed |
| US-20070265326-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-11-15 | — | — | US | disclosed |
| WO-2007122165-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265326-A1 | NOVEL COMPOUNDS | CCL11, MRGPRX2, LTB4R2 | NR3C1 190/4885CCR1 70/4885MEN1 4193/4885 |
| US-20090111866-A1 | Novel Compounds | CCL11, MRGPRX2, LTB4R2 | NR3C1 190/4885CCR1 70/4885MEN1 4193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.